acute-myeloid-leukemia

Documents about acute-myeloid-leukemia

• Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation#877917ClinicalTrials.gov
• Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant#981826ClinicalTrials.gov
• Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML#827014ClinicalTrials.gov
• A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old#907084ClinicalTrials.gov
• Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients#359885Gestión del Repositorio Documental de la Universidad de Salamanca
• CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML#810479ClinicalTrials.gov
• A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies#884447ClinicalTrials.gov
• Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors#992821ClinicalTrials.gov
• A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies#812777ClinicalTrials.gov
• A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML#833731ClinicalTrials.gov
• Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia#856992ClinicalTrials.gov
• Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation#828725ClinicalTrials.gov
• Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome#865414ClinicalTrials.gov
• A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy#899891ClinicalTrials.gov
• Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia#914150ClinicalTrials.gov
• A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies#882824ClinicalTrials.gov
• A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)#826379ClinicalTrials.gov
• Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR#836573ClinicalTrials.gov
• Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS#913392ClinicalTrials.gov
• National Cancer Institute "Cancer Moonshot Biobank"#810468ClinicalTrials.gov
• Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN#861618ClinicalTrials.gov